Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Group 1: Dover Corporation - Dover Corporation reported better-than-expected earnings for the first quarter on April 24, leading to a recommendation for purchase by Jim Cramer [1] - Dover shares gained 1.1% to close at $177.97 [5] Group 2: Arrowhead Pharmaceuticals - Arrowhead Pharmaceuticals initiated a Phase 1/2a study of ARO-ALK7 for the treatment of obesity, although it was noted that the company does not currently generate revenue [1] - Arrowhead Pharmaceuticals shares gained 1.3% to settle at $16.61 [5] Group 3: Snowflake Inc. - Snowflake Inc. reported first-quarter revenue of $1.04 billion, exceeding analyst estimates of $1.01 billion, along with adjusted earnings of 24 cents per share, surpassing estimates of 21 cents [2] - Snowflake shares fell 0.5% to close at $209.15 [5] Group 4: Fluor Corporation - Fluor Corporation posted mixed first-quarter 2025 results on May 2, with revenue growing 6.6% year-over-year to $3.982 billion, but missing the consensus of $4.18 billion [3] - Adjusted EPS improved to 73 cents from 47 cents a year ago, exceeding the consensus of 50 cents [3] - Fluor shares gained 5.4% to settle at $43.39 [5]